Therapeutic Asset Ratings

131 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Inclisiran Acute Coronary Syndrome	Novartis Pharmaceuticals	P3	B (60)
Inclisiran Atherosclerotic Cardiovascular Disease	Novartis Pharmaceuticals	P3	B (60)
Nucresiran hATTR-PN	Alnylam Pharmaceuticals	P3	B (60)
Sepofarsen Neurologic Manifestations	Laboratoires Thea	P2/3	B (59)
Olaptesed Pegol Metastatic Pancreatic Cancer	TME Pharma AG	P2	B (58)
Tilsotolimod Malignant Melanoma	A.J.M. van den Eertwegh	P2	B (58)
Mtl-Cebpa Hepatitis B	Mina Alpha Limited	P2	B (57)
Mtl-Cebpa Hepatitis C	Mina Alpha Limited	P2	B (57)
RNA, (Am-sp-(2?-deoxy-2?-fluoro)G-sp-Am-Um-Am-Gm-(3??3?)-[1-de-?-D-ribofuranosyl-1-[(2S)-2,3-dihydroxypropyl]]m5U-(2??5?)-Cm-Cm-Am-Um-Gm-Cm-(2?-deoxy-2?-fluoro)A-Am-(2?-deoxy-2?-fluoro)A-Am-Gm-Cm-Am-Um-sp-Um-sp-Cm), complex with RNA (Am-sp-Um-sp-Gm-Cm-Um-Um-(2?-deoxy-2?-fluoro)U-Um-(2?-deoxy-2?-fluoro)G-(2?-deoxy-2?-fluoro)C-(2?-deoxy-2?-fluoro)A-Um-Gm-Gm-Am-Cm-Um-Am-Um-Cm-Um) 3?-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-?-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-?-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate] (1:1) Metabolic Dysfunction-Associated SteatoHepatitis (MASH)	Regeneron Pharmaceuticals	P2	B (57)
Mtl-Cebpa Hepatocellular Carcinoma	Mina Alpha Limited	P2	CCC (55)
bp1001 Acute Myeloid Leukemia	Bio-Path Holdings, Inc.	P2	CCC (54)
all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methyl-Pthiouridylyl-( 3'?5')-P-thiothymidylyl-(3'?5')-P-thiothymidylyl-(3'?5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'?5')-Pthiothymidylyl-( 3'?5')-P-thiothymidylyl-(3'?5')-2'-deoxy-Pthioadenylyl-( 3'?5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'?5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-Pthioadenylyl-( 3'?5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methyluridine Mild Cognitive Impairment Due to Alzheimer's Disease	Biogen	P2	CCC (53)
Avicursen Duchenne Muscular Dystrophy	Percheron Therapeutics	P2	CCC (53)
Cldn6 Rna-Lpx Extragonadal Germ Cell Tumor	BioNTech SE	P2	CCC (53)
Cldn6 Rna-Lpx Testicular Germ Cell Tumor	BioNTech SE	P2	CCC (53)
Mivelsiran Down Syndrome-Associated Alzheimer's Disease (DS-AD)	Alnylam Pharmaceuticals	P2	CCC (53)
Nusinersen Anti-myostatin	Scholar Rock, Inc.	P2	CCC (53)
Nusinersen Neuromuscular Manifestations	Scholar Rock, Inc.	P2	CCC (53)
Nusinersen Spinal Muscular Atrophy Type 2	Scholar Rock, Inc.	P2	CCC (53)
Nusinersen Spinal Muscular Atrophy Type 3	Scholar Rock, Inc.	P2	CCC (53)
Vidutolimod Melanoma	National Cancer Institute (NCI)	P2/3	CCC (52)
Defibrotide Sickle Cell Disease	New York Medical College	P2	CCC (51)
rct2100 Cystic Fibrosis	ReCode Therapeutics	P2	CCC (51)
DNA, D(3'-AMINO-3'-DEOXY-P-THIO)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-HYDROXY-3-((1-OXOHEXADECYL)AMINO)PROPYL) HYDROGEN PHOSPHOROTHIOATE) Acute Myeloid Leukemia	Douglas Tremblay	P2	CCC (50)
Nelitolimod Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (50)

Showing 26 to 50 of 131 assets

PreviousPage 2 of 6Next